PEG MGF (2 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection daily. Pegylation extends the half-life of MGF, which allows systemic once-daily sub-Q dosing instead of the frequent intramuscular injections required by native MGF. At 2 mg/mL every dose in this protocol falls between 10 and 25 units, so each one is a clear, readable draw on a U-100 insulin syringe and none of them need splitting across two injections. Doses step up every 2 weeks rather than all at once, and sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation. Injections are given slowly, with a few seconds of pause before the needle is withdrawn. Timing around training sessions is worth considering, though optimal timing has not been established in human studies.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: the protocol opens at 200 mcg daily, which is 10 units (0.10 mL), to establish tolerance at the lowest step.
• Weeks 3 to 4: the daily dose steps up to 300 mcg, which is 15 units (0.15 mL).
• Weeks 5 to 6: the daily dose steps up to 400 mcg, which is 20 units (0.20 mL).
• Weeks 7 to 8: the protocol reaches its top dose of 500 mcg daily, which is 25 units (0.25 mL), and that dose is held if the course is extended to 12 or 16 weeks.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 2 mg/mL, 1 unit = 0.01 mL » 20 mcg on a U-100 insulin syringe, so 200 mcg = 10 units (0.10 mL) and 500 mcg = 25 units (0.25 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid repeated freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• A reconstituted 2 mg vial holds 2000 mcg at 2 mg/mL, which is 10 daily doses at 200 mcg and 4 daily doses at 500 mcg, so each vial is labeled with its reconstitution date and finished within that window.

Supplies Needed

Planning below is based on the 8 week daily protocol with gradual titration, which works out to 1.4 mg in the opening week and 3.5 mg per week at the top dose, with figures also shown for the 12 and 16 week extensions.

Peptide Vials (PEG MGF, 2 mg vial):

• The 8 week titration uses about 19.6 mg in total, which is roughly 10 vials; extending to 12 weeks at the top dose brings the total to about 33.6 mg, roughly 17 vials, and 16 weeks to about 47.6 mg, roughly 24 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, since every dose sits between 10 and 25 units and fits a single syringe.
• Full cycle: 56 syringes across 8 weeks, 84 across 12 weeks, and 112 across 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 2 mg vial takes 1.0 mL of bacteriostatic water, so one 10 mL bottle covers 10 vials, which is 1 bottle for the 8 week course (10 vials), 2 bottles for 12 weeks (17 vials), and 3 bottles for 16 weeks (24 vials).

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 14 per week.
• Full cycle: 112 swabs across 8 weeks and 224 across 16 weeks, so one 100 count box covers about 7 weeks.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for every injection and dispose of them in a sharps container.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation.
• Inject slowly and wait a few seconds before withdrawing the needle.
• Document the daily dose and the site rotation to maintain consistency across an 8 to 16 week course.
• At 2 mg/mL the whole dose range reads cleanly on a U-100 syringe, which is the reason this protocol reconstitutes a 2 mg vial in 1.0 mL rather than a smaller volume that would compress 200 mcg into a 2 unit draw.
• Regulatory Note: PEG MGF has no approved therapeutic indication and no clinical trials of it have been completed. Effects have been demonstrated in animal and cell models only, and safety and efficacy in humans remain unestablished. For research use only; not for human consumption.

How This Works

MGF is a splice variant of IGF-1 that is expressed in muscle tissue following mechanical loading or damage. Unlike systemic IGF-1, MGF acts locally to activate satellite cells and initiate muscle repair processes through its unique C-terminal E peptide domain. Pegylation of MGF extends its half-life, allowing for once-daily subcutaneous administration instead of the frequent local injections required for native MGF. Animal studies have shown that MGF analogues can enhance muscle regeneration, bone healing, and cartilage repair when administered over several weeks.

Benefits & Side Effects

Observations from the published record.

• Animal studies demonstrate enhanced muscle, bone, and cartilage regeneration with MGF analogues administered over multiple weeks.
• MGF promotes myogenic precursor cell proliferation and improves muscle repair in models of injury or depletion.
• Mechano growth factor E peptide has been reported to promote osteoblast proliferation and bone-defect healing in rabbits.
• No human clinical trials have been completed; safety and efficacy in humans remain unestablished.
• Generally well tolerated in preclinical models, though mild injection site reactions may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Combine with progressive resistance training to maximize muscle growth signals and satellite cell activation.
• Maintain adequate protein intake of 1.6 to 2.2 g/kg body weight daily to support muscle protein synthesis.
• Prioritize sleep of 7 to 9 hours nightly and manage training stress to optimize recovery and adaptation.
• Consider timing around training sessions, though optimal timing has not been established in human studies.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Goldspink G. MGF: a local growth factor or a local tissue repair factor? (Physiological Society).
2. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans (In Vivo).
3. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits (International Orthopaedics).
4. A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success (American Journal of Transplantation).